Evidence map›Paper›PMID 22511467›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2012

Cancer prognostics by direct detection of p53-antibodies on gold surfaces by impedance measurements.

Elisabet Prats-Alfonso, Xavier Sisquella, Nadia Zine, Gemma Gabriel, Anton Guimerà, F Javier del Campo, Rosa Villa, Adam H Eisenberg, Milan Mrksich, Abdelhamid Errachid and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 21 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Elisabet Prats-AlfonsoInstitute for Research in Biomedicine, Barcelona Science Park, University of Barcelona, Baldiri Reixac 10, Barcelona, Spain. epratsal@gmail.com
Xavier Sisquella
Nadia Zine
Gemma Gabriel
Anton Guimerà
F Javier del Campo
Rosa Villa
Adam H Eisenberg
Milan Mrksich
Abdelhamid Errachid
Jordi Aguiló
Fernando Albericio
Universitat Autònoma de Barcelona · ESNorthwestern University · USUniversité Claude Bernard Lyon 1 · FRBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESInstitut de Microelectrònica de Barcelona · ESInstitute for Research in Biomedicine · ESUniversitat de Barcelona · ES

Funding

Theranostic Magnetic Nanostructures for the Molecular Imaging of CancerU54CA151880 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MIRKIN, CHAD A. · 2010 to 2014
$11.5M
Howard Hughes Medical InstituteNCI NIH HHS U54 CA151880
6 · The paper itself

Abstract

The identification and measurement of biomarkers is critical to a broad range of methods that diagnose and monitor many diseases. Serum auto-antibodies are rapidly becoming interesting targets because of their biological and medical relevance. This paper describes a highly sensitive, label-free approach for the detection of p53-antibodies, a prognostic indicator in ovarian cancer as well as a biomarker in the early stages of other cancers. This approach uses impedance measurements on gold microelectrodes to measure antibody concentrations at the picomolar level in undiluted serum samples. The biosensor shows high selectivity as a result of the optimization of the epitopes responsible for the detection of p53-antibodies and was validated by several techniques including microcontact printing, self-assembled-monolayer desorption ionization (SAMDI) mass spectrometry, and adhesion pull-off force by atomic force microscopy (AFM). This transduction method will lead to fast and accurate diagnostic tools for the early detection of cancer and other diseases.

Indexed as

Electric ImpedanceAntibodiesBiosensing TechniquesFemaleHumansMicroscopy, Atomic ForceTumor Suppressor Protein p53AntibodiesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID22511467
PMCPMC3753068
OpenAlexW2031766226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.